DonCorleone77 Posted - 4 days ago

$TAK $ALPMY $SMFG Takeda, Astellas Pharma and Sumitomo Mitsui to establish joint venture company Takeda (TAK), Astellas Pharma (ALPMY), and Sumitomo Mitsui (SMFG) announced that the three companies signed a master agreement on April 22 to establish a joint venture company. The new company will be dedicated to the incubation of early drug discovery programs, primarily originating from Japan and toward the creation of innovative therapeutics. In addition to establishing the joint venture company, Takeda and Astellas will provide support to the joint venture company leveraging their expertise gained from global drug discovery research and development, aiming to accelerate open innovation in early-stage drug discovery, and toward the creation of start-up companies for the benefit of society. The joint venture company plans to begin incubation activities by collaboratively working with academia, pharmaceutical companies, and start-up companies across Japan to enable access to potentially transformative early drug discovery programs. The three companies will further discuss the details of the agreement to complete the inception of the joint venture company and commence operations, aiming for a swift launch of the new incubation activities.

BiotechJedi1728 Posted - 1 month ago

@Snake2010 $BAYRY is instilling cost savings measures for the company. That frees up dollars for acquisitions. I wouldn’t be surprised if it is in play. 🤷🏻‍♂️ but there is $OGN and $ALPMY too.

maphere Posted - 1 month ago

$CLSD $ALPMY Clearside injector included in a new world patent from Astellas: Publication Date 29.02.2024 WO2024044134 - PHOTORECEPTOR RESCUE CELL (PRC) COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR DISORDERS Applicants ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE [US]/[US] The photoreceptor rescue cells can be administered via a device, for example a syringe, the Oxulumis Illuminated Suprachoroidal Microcatheter (Oxular), P0D3 Gold (Oxular), Oxuspheres (Oxular), SCS microinjector (Clearside Biomedical), Orbit SDS (Gyroscope), via an implant, via a cell seeded substrate or an implantable membrane, either alone or in combination with another cell type, for example retinal pigment epithelial cells. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024044134&_cid=P10-LTN0YA-81578-1

mojo999 Posted - 02/28/24

$CTMX [PART 2] ⭐EGFRxCD3 T-cell engager initial Phase 1a dose escalation data 2H - IND application filed for conditional approval ⭐Activated EpCAM-directed ADC for EpCAM positive tumors expected in the 1H 2024 ⭐Heavy weight smart $ biotech investors are largest shareholders: BVF, Tang etc ⭐7 ADCs in partnerships with 5 big pharmas:$AMGN, $ALPMY, $BMY, $REGN, $MRNA ⭐Any of large pharma partners could easily take them out a multiples to the current price. Appears grossly undervalued even with recent move. Looks ripe for continued revaluation. https://twitter.com/smantel/status/1762935786306232461

Jnbond7 Posted - 2 months ago

$ALPMY In regards to Veozah, $ALPMY and pharmacies need to get their act together. Pharmacies aren't honoring Veozah-saving cards. It's also difficult to process Veozah through insurance. Veozah is already expensive w/o the need of making things into an administrative nightmare. Probably the reason why $ALPMY is down; if not, all the shenanigans definitely don't help.

DonCorleone77 Posted - 01/30/24

$ALPMY Astellas Pharma announces strategic collaboration with Mass General Brigham Astellas Pharma announced that it has entered into a strategic collaboration with Mass General Brigham that is focused on translational medicine and early development to establish an integrated approach to scientific advancement and clinical expertise. Initial projects of mutual interest will be focused in key areas of R&D investment for Astellas, including oncology, rare disease, and cell and gene therapy. Through the alliance, Astellas and Mass General Brigham aim to: Accelerate innovation through collaborative research, as well as exploring and expanding new research frontiers; translate innovative research into clinical trials and actionable solutions that address serious unmet needs and aim to improve healthcare for all; leverage scientific and clinical expertise to inform and accelerate the development of novel therapies.

DonCorleone77 Posted - 3 months ago

$PFE $ALPMY EMA validates Type II variation application for Padcev-Keytruda combination Pfizer (PFE) and Astellas Pharma (ALPMY) announced that on January 26 the European Medicines Agency validated for review a Type II variation application for PADCEV with KEYTRUDA as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer. If approved, PADCEV with KEYTRUDA has the potential to change the treatment paradigm, becoming the first combination treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC. Globally, approximately 573,000 new cases of bladder cancer and 212,000 deaths are reported annually.1 It is estimated that approximately 200,000 people in Europe are diagnosed with bladder cancer each year.

STCKPRO Posted - 3 months ago

$ALPMY NEW ARTICLE : US FDA declines to approve Astellas' gastric cancer drug https://www.stck.pro/news/ALPMY/72094444/

STCKPRO Posted - 3 months ago

$ALPMY NEW ARTICLE : Astellas Provides Update on Zolbetuximab Biologics License Application in U.S. https://www.stck.pro/news/ALPMY/72091874/

DonCorleone77 Posted - 3 months ago

$ALPMY 2 of 2 - FDA says it cannot approve Astellas BLA for zolbetuximab by PDUFA action date ....The FDA stated that the agency cannot approve the BLA by the Prescription Drug User Fee Act (PDUFA) action date of January 12, 2024, due to unresolved deficiencies following its pre-license inspection of a third-party manufacturing facility for zolbetuximab. The FDA has not raised any concerns related to the clinical data, including efficacy or safety, of zolbetuximab, and is not requesting additional clinical studies. Astellas is working closely with the FDA and the third-party manufacturer to establish a timeline to quickly resolve the agency's feedback. No other Astellas products are affected.

DonCorleone77 Posted - 3 months ago

$ALPMY 1 of 2 - FDA says it cannot approve Astellas BLA for zolbetuximab by PDUFA action date Astellas Pharma announced the U.S. Food and Drug Administration (FDA) issued a complete response letter on January 4, 2024, regarding the Biologics License Application (BLA) for zolbetuximab, an investigational agent for the treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive....

Stock_Titan Posted - 3 months ago

$ALPMY Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.

NOCTURNALCREATURE Posted - 3 months ago

$ALPMY why this multi billion company is not even listed on major markets? Ridicolous

BiotechJedi1728 Posted - 3 months ago

$DARE Clown boy thinks a big pipeline is bad. lol 😂 Every product is another asset to out-license or make it an attractive buyout for bigger companies in women’s health like $OGN and $ALPMY He is talking about a cruise. 😆 Sabrina is cornering billion dollar markets 🤦🏻‍♂️

TalkMarkets Posted - 12/31/23

$1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal $AZN $ALPMY $GRCL $LIAN $IVBXF https://talkmarkets.com/content/global-markets/week-in-review-17-billion-collaboration-between-elpiscience-and-astellas-is-final-2023-deal?post=425016&userid=123969

BiotechJedi1728 Posted - 12/30/23

HRT-1 updated to mature product on website with orange color and the data says Ph3 next: https://journals.lww.com/menopausejournal/fulltext/2023/09000/a_phase_1_2,_open_label,_parallel_group_study_to.11.aspx Who is going to partner with them? $ALPMY ? they have menopause products already. $OGN already partnered on Xaciato. Best product on the market as it has both estradiol and progesterone, and ring lets you deliver over a month. Every thing else is daily. Going to be go-to in this space.

DonCorleone77 Posted - 12/28/23

$ALPMY Astellas, Elpiscience enter license agreement for bi-specific macrophage engager Elpiscience Biopharma and Astellas Pharma announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019 and another program. The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two additional programs to be included in the collaboration. If Astellas exercises its option, Elpiscience will grant Astellas the exclusive right to further research, develop, manufacture and commercialize the products for each program.

STCKPRO Posted - 12/28/23

$ALPMY NEW ARTICLE : Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager https://www.stck.pro/news/ALPMY/70934985/

Stock_Titan Posted - 12/28/23

$ALPMY Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager

STCKPRO Posted - 12/27/23

$ALPMY NEW ARTICLE : Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager https://www.stck.pro/news/ALPMY/70927348/

Stock_Titan Posted - 4 months ago

$ALPMY Astellas Completes Acquisition of Propella Therapeutics

Theprofoundpondguy Posted - 4 months ago

$ALPMY

Gretathumb Posted - 4 months ago

$ALPMY l Approval in the UK https://amp.theguardian.com/society/2023/dec/18/veoza-fezolinetant-menopause-drug-hot-flushes-wins-uk-approval

Stock_Titan Posted - 4 months ago

$ALPMY EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children Article Available on StockTitan Website.

DonCorleone77 Posted - 4 months ago

$ALPMY $PFE Pfizer, Astellas Pharma announce FDA approval for Padcev Pfizer (PFE) and Astellas Pharma (ALPMY) announced that the FDA has approved Padcev for the treatment of adult patients with locally advanced or metastatic urothelial cancer, or la/mUC. This combination is the first approved to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC.

STCKPRO Posted - 4 months ago

$ALPMY NEW ARTICLE : Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics https://www.stck.pro/news/ALPMY/70127216/

STCKPRO Posted - 4 months ago

$ALPMY NEW ARTICLE : Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause https://www.stck.pro/news/ALPMY/69937386/

BiotechJedi1728 Posted - 4 months ago

@Thecannonbull Heh. Still an idiot. No one is liquidating a company generating revenue or that now has a billion dollar product in Phase3. I understand that is hard to get in your little brain but Fortune 500 companies like Bayer and Organon seem to get it. But it might be them or $PFE or $ALPMY $GSK or $ABBV that takes a 10% stake here. 12M shares in one shot to bolster the stock while they support the Ph3/marketing/sales of Sildenafil or HRT-1 products that are ready for Ph3. Seen it before. Will see it again. Many sh!tbirds and roaches 🪳 on this site who are tied to hedge funds shorting the crap out this stock will say this will never happen, but they underestimate how much money is at stake for a menopause product like HRT-1. $1-$2B product. Just ask Astellas how much they think Veozah will make for them. Some know the value. Others get left in the dust.

DonCorleone77 Posted - 11/29/23

$ALPMY 2 of 2 - Astellas Pharma's fezolinetant shows efficacy in Phase 3b VMS trial ....For the key secondary endpoint of mean change from baseline in the severity of moderate to severe VMS, fezolinetant 45 mg demonstrated a statistically significant reduction of -0.39 vs. placebo. For the secondary endpoint of mean change from baseline in patient-reported sleep disturbance, fezolinetant 45 mg demonstrated a statistically significant reduction of -2.5 vs. placebo. Treatment-emergent adverse events were reported by 65% of patients in the fezolinetant group vs. 61% in the placebo group. The most common TEAEs were COVID-19, headache and fatigue.

DonCorleone77 Posted - 11/29/23

$ALPMY 1 of 2 - Astellas Pharma's fezolinetant shows efficacy in Phase 3b VMS trial Astellas Pharma will present 24-week results from the Phase 3b DAYLIGHT clinical trial examining the efficacy and safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms - VMS - associated with menopause in women considered unsuitable for hormone therapy, at the 15th Congress of the European Society of Gynecology in Amsterdam. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. The study of more than 450 women considered unsuitable for hormone therapy met all primary and secondary endpoints at 24 weeks. For the primary endpoint of mean change from baseline in the frequency of moderate to severe VMS, fezolinetant 45 mg demonstrated a statistically significant reduction of -1.93 vs. placebo....